Damien L Smith, MD
Urology · Santa Cruz
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
Offices
6 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Dominican Hospital · Sutter Maternity & Surgery Center of Santa Cruz. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Smith’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A112593 · Current
Licensed to practise in California · since 2010 · expires 2027-11-30 · University of Missouri-Columbia School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
- Sutter Maternity & Surgery Center of Santa CruzSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · No emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 85% would definitely recommend itNo overall ratingNo measure marked better or worse than the national rate
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Sutter Maternity & Surgery Center of Santa Cruz
Behind the star rating — Deaths: 0 better, 1 the same, 0 worse of 1 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 4 the same, 0 worse of 4 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.04 (0 to 2.12) · 59 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.01 (0.5 to 1.52) | No different | Jul 2022 – Jun 2024 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 63 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.44) · 118 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.05 to 0.49) · 116 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.36 (0.77 to 5.95) · 113 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.37) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.28 (0.56 to 4) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.41 (0 to 18.05) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.75 (2.52 to 10.98) · 102 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.23 to 3.28) · 42 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0 to 1.94) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 30 cases | None | Apr 2023 – Mar 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.7 (9.2 to 14.9) · 3,197 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 506 cases | No different | Jan 2024 – Dec 2024 |
What patients said (203 patients answered, 24% of those asked)
| Cleanliness | 5 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 5 |
| Overall hospital rating | 5 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 84% |
| Nurses "always" communicated well | 83% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 93% |
| Yes, staff "did" give patients information about help after discharge | 96% |
| Doctors "always" explained things so they could understand | 79% |
| Doctors "always" listened carefully | 83% |
| Doctors "always" treated them with courtesy and respect | 88% |
| Patients who gave a rating of "9" or "10" (high) | 87% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 69% |
| "YES", patients would definitely recommend the hospital | 85% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$360,851
Medicare paid this office $360,851 for 784 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 430 | $52,230 | $94 |
| Diagnostic exam of bladder and urethra using an endoscope | 108 | $27,128 | $210 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $20,499 | None |
| New patient visit (45+ min) | 151 | $18,060 | $120 |
| Long return visit (40+ min) | 98 | $17,492 | $143 |
See all 28 services
| Return visit (30+ min) | 430 | $52,230 | $94 |
| Diagnostic exam of bladder and urethra using an endoscope | 108 | $27,128 | $210 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $20,499 | None |
| New patient visit (45+ min) | 151 | $18,060 | $120 |
| Long return visit (40+ min) | 98 | $17,492 | $143 |
| Short return visit (20+ min) | 222 | $16,244 | $67 |
| Simple surgical subtotal removal of prostate using laparoscope | 13 | $10,602 | $816 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 511 | $8,405 | $13 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 19 | $6,222 | $283 |
| New patient visit (60+ min) | 31 | $5,372 | $173 |
| Needle biopsy of prostate gland using image guidance | 15 | $4,693 | $313 |
| Limited ultrasound scan of pelvis | 102 | $4,304 | $38 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $4,221 | $325 |
| Ultrasound scan of pelvic region through rectum | 34 | $4,135 | $122 |
| Dilation of urethra using an endoscope | 13 | $3,918 | $280 |
| Simple change of bladder tube | 13 | $3,478 | $79 |
| Simple bladder irrigation and/or instillation | 35 | $3,323 | $66 |
| Biopsy of prostate gland | 16 | $2,721 | $170 |
| Manual urinalysis test with examination using microscope, automated | 440 | $2,028 | $3 |
| Simple insertion of temporary bladder tube | 19 | $1,908 | $52 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 29 | $1,598 | $20 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $1,517 | $32 |
| Ultrasound measurement of bladder capacity after voiding | 142 | $1,439 | $9 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,167 | $106 |
| Insertion of stent in ureter using an endoscope | 11 | $960 | $80 |
| Ultrasound scan of pelvic region through rectum | 19 | $533 | $27 |
| Injection of drug or substance under skin or into muscle | 14 | $364 | $13 |
| Electronic assessment of bladder emptying | 18 | $135 | $8 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Prostate resection | 21 | More than 81% of doctors who do this |
| Removal of skin lesions | 1-10 | None |
Who their Medicare patients are
784 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 12% · Women 19% · Also on Medicaid 14% · Health risk score 1.10. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 65% · Cancer 34% · Chronic kidney disease 24% · Coronary heart disease 23% · Diabetes 22% · Atrial fibrillation 22% · Depression 16% · Heart failure 13% · COPD 8% · Dementia 5% · Stroke 5%.
The office billed $1,831,525, Medicare allowed $476,253 and paid $360,851; for 19,170 services of 87 kinds; $110,674 of it was for drugs given in the office and $250,177 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 784 | 19,170 | 75 | 1.10 | $1,831,525 | $360,851 |
| 2023 | 755 | 13,367 | 75 | 1.12 | $1,464,424 | $294,865 |
| 2022 | 694 | 8,889 | 75 | 1.11 | $1,255,775 | $264,727 |
| 2021 | 738 | 15,632 | 75 | 1.23 | $1,604,397 | $319,244 |
| 2020 | 670 | 13,378 | 74 | 1.29 | $1,567,366 | $304,935 |
| 2019 | 581 | 23,337 | 74 | 1.26 | $1,095,253 | $240,029 |
| 2018 | 402 | 6,822 | 73 | 1.45 | $761,239 | $159,396 |
| 2017 | 283 | 1,586 | 73 | 1.30 | $560,402 | $111,793 |
| 2016 | 135 | 619 | 74 | 1.09 | $212,342 | $44,440 |
| 2015 | 78 | 366 | 73 | 1.34 | $50,177 | $33,497 |
| 2014 | 128 | 708 | 74 | 1.27 | $85,272 | $60,627 |
| 2013 | 119 | 681 | 73 | 1.34 | $65,024 | $47,225 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 28 services
| Return visit (30+ min) | 462 | $58,478 | $95 |
| Diagnostic exam of bladder and urethra using an endoscope | 93 | $26,633 | $220 |
| New patient visit (45+ min) | 117 | $15,873 | $136 |
| Long return visit (40+ min) | 74 | $12,529 | $151 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $10,014 | None |
| Short return visit (20+ min) | 95 | $7,279 | $71 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $6,657 | $605 |
| New patient visit (60+ min) | 40 | $6,556 | $164 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 16 | $6,172 | $343 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 19 | $5,517 | $276 |
| Limited ultrasound scan of pelvis | 117 | $5,287 | $41 |
| Insertion of lower leg neurostimulator electrode | 27 | $5,075 | $110 |
| Biopsy of prostate gland | 20 | $4,028 | $201 |
| Simple change of bladder tube | 19 | $3,515 | $82 |
| Ultrasound scan of pelvic region through rectum | 21 | $2,642 | $126 |
| Simple bladder irrigation and/or instillation | 26 | $2,347 | $69 |
| Insertion of stent in ureter using an endoscope | 24 | $2,311 | $83 |
| Manual urinalysis test with examination using microscope, automated | 433 | $2,123 | $3 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,093 | $110 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 44 | $1,945 | $20 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,813 | $67 |
| Simple insertion of temporary bladder tube | 21 | $1,640 | $50 |
| Ultrasound measurement of bladder capacity after voiding | 143 | $1,580 | $10 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $835 | $42 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $797 | $32 |
| Ultrasonic guidance during surgery | 11 | $468 | $43 |
| Imaging of urinary tract following injection of a contrast agent | 15 | $354 | $21 |
| Injection of drug or substance under skin or into muscle | 12 | $243 | $13 |
2022: 25 services
| Return visit (30+ min) | 484 | $58,615 | $96 |
| Diagnostic exam of bladder and urethra using an endoscope | 108 | $31,761 | $221 |
| New patient visit (45+ min) | 96 | $12,751 | $133 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $11,987 | None |
| Crushing of stone of ureter with insertion of stent using an endoscope | 25 | $10,505 | $362 |
| New patient visit (60+ min) | 50 | $9,644 | $193 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 28 | $9,472 | $296 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 13 | $8,126 | $625 |
| Long return visit (40+ min) | 46 | $7,474 | $153 |
| Limited ultrasound scan of pelvis | 113 | $4,665 | $39 |
| Biopsy of prostate gland | 19 | $4,079 | $215 |
| Short return visit (20+ min) | 43 | $3,259 | $71 |
| Insertion of stent in ureter using an endoscope | 27 | $2,991 | $93 |
| Ultrasound scan of pelvic region through rectum | 26 | $2,878 | $111 |
| Manual urinalysis test with examination using microscope, automated | 526 | $2,396 | $3 |
| Simple bladder irrigation and/or instillation | 26 | $2,059 | $66 |
| Simple insertion of temporary bladder tube | 21 | $1,805 | $53 |
| Simple change of bladder tube | 12 | $1,357 | $75 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $1,322 | $73 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 42 | $1,003 | $19 |
| Ultrasound measurement of bladder capacity after voiding | 91 | $988 | $9 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $687 | $33 |
| Imaging of urinary tract following injection of a contrast agent | 16 | $406 | $21 |
| Injection of drug or substance under skin or into muscle | 12 | $249 | $13 |
| Imaging guidance for procedure, 60 minutes or less | 14 | $221 | $13 |
2021: 29 services
| Return visit (30+ min) | 371 | $51,235 | $101 |
| Diagnostic exam of bladder and urethra using an endoscope | 106 | $30,250 | $212 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 39 | $28,013 | None |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 15 | $15,504 | $1,034 |
| Injection, testosterone undecanoate, 1 mg | 13 | $14,177 | None |
| New patient visit (45+ min) | 108 | $13,372 | $124 |
| Long return visit (40+ min) | 77 | $11,223 | $137 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 17 | $10,534 | $620 |
| Insertion of lower leg neurostimulator electrode | 41 | $9,608 | $113 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 31 | $9,480 | $279 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 23 | $8,609 | $344 |
| Short return visit (20+ min) | 73 | $5,898 | $73 |
| Biopsy of prostate gland | 21 | $4,642 | $221 |
| New patient visit (60+ min) | 22 | $4,126 | $188 |
| Simple change of bladder tube | 19 | $4,050 | $84 |
| Limited ultrasound scan of pelvis | 91 | $3,782 | $39 |
| Ultrasound scan of pelvic region through rectum | 24 | $3,453 | $133 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 16 | $3,118 | $183 |
| Simple bladder irrigation and/or instillation | 34 | $3,071 | $70 |
| Simple insertion of temporary bladder tube | 26 | $2,919 | $56 |
| Manual urinalysis test with examination using microscope, automated | 509 | $2,783 | $3 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 89 | $2,765 | $20 |
| Insertion of stent in ureter using an endoscope | 27 | $2,562 | $88 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 33 | $1,668 | $30 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $924 | $77 |
| Ultrasound measurement of bladder capacity after voiding | 79 | $844 | $9 |
| Imaging of urinary tract following injection of a contrast agent | 32 | $779 | $22 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $723 | $33 |
| Injection of drug or substance under skin or into muscle | 26 | $398 | $13 |
2020: 29 services
| Leuprolide acetate (for depot suspension), 7.5 mg | 41 | $34,763 | None |
| Return visit (30+ min) | 200 | $22,998 | $95 |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 18 | $19,573 | $1,087 |
| Diagnostic exam of bladder and urethra using an endoscope | 71 | $17,192 | $185 |
| New patient visit (45+ min) | 136 | $16,395 | $121 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 36 | $16,216 | $386 |
| Insertion of lower leg neurostimulator electrode | 67 | $14,629 | $112 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 41 | $11,866 | $264 |
| Injection, testosterone undecanoate, 1 mg | 11 | $11,529 | None |
| Short return visit (20+ min) | 166 | $10,750 | $52 |
| Long return visit (40+ min) | 67 | $8,487 | $123 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $7,086 | $644 |
| Biopsy of prostate gland | 28 | $6,015 | $215 |
| Simple bladder irrigation and/or instillation | 45 | $5,335 | $67 |
| Insertion of stent in ureter using an endoscope | 44 | $4,948 | $95 |
| Simple change of bladder tube | 34 | $4,853 | $80 |
| Ultrasound scan of pelvic region through rectum | 28 | $3,761 | $134 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 0.5-2.0 cm | 16 | $3,229 | $190 |
| Removal of lymph nodes of both sides of pelvis using an endoscope | 12 | $3,011 | $251 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 32 | $2,435 | $33 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 72 | $2,419 | $20 |
| Simple insertion of temporary bladder tube | 21 | $2,395 | $53 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 26 | $2,361 | $87 |
| Manual urinalysis test with examination using microscope, automated | 402 | $2,254 | $3 |
| Imaging of urinary tract following injection of a contrast agent | 61 | $1,888 | $22 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 36 | $1,539 | $29 |
| Ultrasound measurement of bladder capacity after voiding | 75 | $890 | $9 |
| Limited ultrasound scan of pelvis | 17 | $723 | $43 |
| Injection of drug or substance under skin or into muscle | 27 | $498 | $12 |
2019: 28 services
| Injection, testosterone undecanoate, 1 mg | 17 | $21,644 | None |
| New patient visit (45+ min) | 152 | $18,919 | $124 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 25 | $18,512 | None |
| Partial removal of kidney using an endoscope | 16 | $16,246 | $956 |
| Short return visit (20+ min) | 166 | $13,506 | $56 |
| Return visit (30+ min) | 117 | $13,227 | $85 |
| Insertion of lower leg neurostimulator electrode | 72 | $12,472 | $105 |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 13 | $9,852 | $758 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 22 | $9,623 | $370 |
| Diagnostic exam of bladder and urethra using an endoscope | 38 | $7,809 | $170 |
| Long return visit (40+ min) | 52 | $6,527 | $117 |
| Biopsy of prostate gland | 27 | $5,882 | $218 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 18 | $4,800 | $240 |
| Simple bladder irrigation and/or instillation | 36 | $3,778 | $63 |
| Ultrasound scan of pelvic region through rectum | 27 | $3,113 | $115 |
| Simple change of bladder tube | 23 | $3,021 | $79 |
| Manual urinalysis test with examination using microscope, automated | 374 | $2,439 | $3 |
| Simple insertion of temporary bladder tube | 23 | $2,134 | $50 |
| Insertion of stent in ureter using an endoscope | 17 | $1,600 | $84 |
| Ultrasound measurement of bladder capacity after voiding | 85 | $1,233 | $10 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 66 | $1,209 | $17 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $1,093 | $33 |
| Injection of drug or substance under skin or into muscle | 36 | $937 | $15 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $915 | $28 |
| Instillation of anti-cancer drug into bladder | 11 | $827 | $64 |
| Imaging of urinary tract following injection of a contrast agent | 29 | $794 | $22 |
| Ultrasonic guidance during surgery | 11 | $625 | $52 |
| Injection, tobramycin sulfate, up to 80 mg | 11 | $70 | None |
2018: 23 services
| New patient visit (45+ min) | 153 | $19,327 | $126 |
| Return visit (30+ min) | 106 | $13,314 | $85 |
| Short return visit (20+ min) | 172 | $11,594 | $53 |
| Surgical removal of prostate and surrounding lymph nodes using an endoscope | 12 | $9,441 | $787 |
| Diagnostic exam of bladder and urethra using an endoscope | 54 | $8,697 | $138 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $7,347 | None |
| Long return visit (40+ min) | 34 | $4,147 | $109 |
| Biopsy of prostate gland | 18 | $3,743 | $208 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 14 | $3,116 | $208 |
| Ultrasound measurement of bladder capacity after voiding | 139 | $2,631 | $13 |
| Simple bladder irrigation and/or instillation | 36 | $2,553 | $61 |
| Ultrasound scan of pelvic region through rectum | 23 | $1,960 | $85 |
| Insertion of stent in ureter using an endoscope | 14 | $1,696 | $113 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,243 | $83 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $1,191 | $32 |
| Simple insertion of temporary bladder tube | 14 | $1,120 | $56 |
| Manual urinalysis test with examination using microscope, automated | 178 | $1,110 | $4 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $650 | $25 |
| Urinalysis, manual test | 119 | $574 | $3 |
| Ultrasonic guidance for needle placement | 12 | $564 | $47 |
| Injection of drug or substance under skin or into muscle | 13 | $411 | $18 |
| Imaging of urinary tract following injection of a contrast agent | 23 | $383 | $15 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $244 | $19 |
2017: 19 services
| New patient visit (45+ min) | 148 | $17,285 | $117 |
| Short return visit (20+ min) | 142 | $11,870 | $56 |
| Diagnostic exam of bladder and urethra using an endoscope | 53 | $8,438 | $136 |
| Return visit (30+ min) | 59 | $6,727 | $84 |
| Biopsy of prostate gland | 25 | $4,707 | $188 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 16 | $4,150 | $259 |
| Ultrasound measurement of bladder capacity after voiding | 135 | $3,088 | $16 |
| New patient visit (60+ min) | 16 | $2,663 | $166 |
| Long return visit (40+ min) | 15 | $2,232 | $117 |
| Ultrasound scan of pelvic region through rectum | 25 | $1,899 | $76 |
| Insertion of device into abdomen with pressure and urine flow rate study | 16 | $1,504 | $94 |
| Urinalysis, manual test | 216 | $1,427 | $3 |
| Simple bladder irrigation and/or instillation | 23 | $1,399 | $47 |
| Ultrasonic guidance for needle placement | 25 | $1,202 | $48 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 13 | $939 | $31 |
| New patient visit (30+ min) | 11 | $701 | $64 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 16 | $459 | $29 |
| Imaging of urinary tract following injection of a contrast agent | 12 | $200 | $14 |
| Electronic assessment of bladder emptying | 12 | $78 | $7 |
2016: 7 services
| New patient visit (45+ min) | 86 | $11,405 | $133 |
| Diagnostic exam of bladder and urethra using an endoscope | 29 | $5,095 | $170 |
| Short return visit (20+ min) | 44 | $3,260 | $58 |
| New patient visit (30+ min) | 30 | $2,564 | $85 |
| Return visit (30+ min) | 14 | $1,500 | $88 |
| Ultrasound measurement of bladder capacity after voiding | 65 | $1,423 | $16 |
| Urinalysis, manual test | 107 | $600 | $3 |
2015: 5 services
| Diagnostic exam of bladder and urethra using an endoscope | 17 | $2,945 | $164 |
| Return visit (30+ min) | 29 | $2,815 | $78 |
| Short return visit (20+ min) | 28 | $1,361 | $40 |
| Ultrasound measurement of bladder capacity after voiding | 29 | $559 | $15 |
| Manual urinalysis test with examination using microscope, non-automated | 48 | $295 | $4 |
2014: 10 services
| Return visit (30+ min) | 51 | $6,397 | $80 |
| New patient visit (45+ min) | 42 | $4,554 | $108 |
| Short return visit (20+ min) | 55 | $4,203 | $52 |
| Diagnostic exam of bladder and urethra using an endoscope | 19 | $3,891 | $162 |
| Biopsy of prostate gland | 13 | $2,273 | $175 |
| Ultrasound scan of pelvic region through rectum | 13 | $995 | $77 |
| Ultrasonic guidance for needle placement | 13 | $782 | $60 |
| Manual urinalysis test with examination using microscope, non-automated | 87 | $689 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 28 | $643 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 15 | $108 | $6 |
2013: 10 services
| New patient visit (45+ min) | 49 | $6,151 | $126 |
| Return visit (30+ min) | 48 | $5,474 | $83 |
| Diagnostic exam of bladder and urethra using an endoscope | 33 | $5,292 | $160 |
| Short return visit (20+ min) | 45 | $3,671 | $56 |
| Ultrasound measurement of bladder capacity after voiding | 41 | $953 | $16 |
| Short return visit | 18 | $794 | $36 |
| Automated urinalysis test | 75 | $448 | $3 |
| Manual urinalysis test with examination using microscope, non-automated | 34 | $175 | $4 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 14 | $120 | $9 |
| Electronic assessment of bladder emptying | 12 | $83 | $7 |
Medicaid work
$8,441 in 2023
Medicaid paid $8,441 for 226 billed services this clinician did in 2023, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 121 | $8,333 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 105 | $108 |
| 2023 | 226 | 2 | 17 | $8,441 |
| 2022 | 202 | 2 | 18 | $4,572 |
| 2021 | 104 | 2 | 17 | $2,954 |
| 2020 | 178 | 2 | 20 | $2,372 |
| 2019 | 242 | 2 | 26 | $1,051 |
| 2018 | 322 | 5 | 26 | $11,108 |
See the largest Medicaid services in earlier years
2022
| Return visit (30+ min) | 70 | $4,371 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 132 | $201 |
2021
| Return visit (30+ min) | 38 | $2,856 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 66 | $98 |
2020
| New patient visit (45+ min) | 15 | $2,138 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 163 | $234 |
2019
| Short return visit (20+ min) | 15 | $665 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 227 | $386 |
2018
| Short return visit (20+ min) | 83 | $5,703 |
| New patient visit (45+ min) | 31 | $3,859 |
| Measurement of post-voiding residual urine and/or bladder capacity by ultrasound, non-imaging | 71 | $1,267 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 90 | $191 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 47 | $88 |
Drugs they prescribed that Part D paid
$155,575
Pharmacies billed $155,575 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,086 generic and fewer than 11 brand-name prescriptions · $155,575 in drug cost · 71 antibiotic prescriptions to 60 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 87 | $55,319 | $636 |
| Orgovyx | 13 | $35,499 | $2,731 |
| Tamsulosin | 454 | $7,861 | $17 |
| Testosterone | 34 | $6,845 | $201 |
| Desmopressin Acetate | 24 | $3,546 | $148 |
See all 18 drugs
| Myrbetriq | 87 | $55,319 | $636 |
| Orgovyx | 13 | $35,499 | $2,731 |
| Tamsulosin | 454 | $7,861 | $17 |
| Testosterone | 34 | $6,845 | $201 |
| Desmopressin Acetate | 24 | $3,546 | $148 |
| Finasteride | 214 | $3,448 | $16 |
| Toviaz | 13 | $3,345 | $257 |
| Trospium Chloride | 55 | $2,996 | $54 |
| Dutasteride | 41 | $1,611 | $39 |
| Solifenacin | 29 | $1,295 | $45 |
| Oxybutynin Chloride Er | 26 | $889 | $34 |
| Megestrol Acetate | 13 | $570 | $44 |
| Alfuzosin Hcl Er | 32 | $552 | $17 |
| Testosterone Cypionate | 14 | $315 | $23 |
| Bicalutamide | 12 | $171 | $14 |
| Ciprofloxacin | 22 | $71 | $3 |
| Amoxicillin-Clavulanate Potass | 11 | $57 | $5 |
| Hydrochlorothiazide | 11 | $23 | $2 |
Year by year
| 2024 | 1,220 | 374 | None | None | $155,575 |
| 2023 | 1,462 | 404 | 2% (25) | 8% | $151,122 |
| 2022 | 1,253 | 364 | None | None | $115,612 |
| 2021 | 1,242 | 370 | 2% (27) | None | $141,483 |
| 2020 | 976 | 322 | 3% (27) | None | $82,919 |
| 2019 | 832 | 254 | 5% (45) | None | $74,080 |
| 2018 | 790 | 190 | 3% (26) | None | $88,555 |
| 2017 | 430 | 124 | 7% (28) | 26% | $55,267 |
| 2016 | 394 | 113 | 4% (15) | 10% | $20,128 |
| 2015 | 1,009 | 231 | 6% (55) | None | $28,427 |
| 2014 | 1,311 | 319 | 10% (133) | None | $47,255 |
| 2013 | 812 | 201 | 8% (63) | 18% | $50,484 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Myrbetriq | 84 | $59,776 | $712 |
| Tamsulosin | 493 | $14,740 | $30 |
| Finasteride | 285 | $7,359 | $26 |
| Testosterone | 31 | $4,015 | $130 |
| Desmopressin Acetate | 23 | $3,927 | $171 |
| Methenamine Hippurate | 32 | $3,593 | $112 |
| Trospium Chloride | 35 | $2,673 | $76 |
| Potassium Citrate Er | 16 | $2,424 | $151 |
| Oxybutynin Chloride Er | 49 | $2,236 | $46 |
| Solifenacin | 13 | $2,089 | $161 |
| Dutasteride | 34 | $1,716 | $50 |
| Bethanechol Chloride | 11 | $938 | $85 |
| Alfuzosin Hcl Er | 30 | $610 | $20 |
| Amoxicillin-Clavulanate Potass | 42 | $450 | $11 |
| Testosterone Cypionate | 11 | $332 | $30 |
| Nitrofurantoin Mono-Macro | 14 | $198 | $14 |
| Hydrocodone-Acetaminophen | 17 | $155 | $9 |
| Ciprofloxacin | 32 | $139 | $4 |
| Sulfamethoxazole-Trimethoprim | 20 | $123 | $6 |
| Hydrochlorothiazide | 16 | $100 | $6 |
| Cephalexin | 15 | $84 | $6 |
| Sildenafil Citrate | 11 | $49 | $4 |
| Amoxicillin | 13 | $47 | $4 |
2022: 17 drugs
| Myrbetriq | 85 | $49,538 | $583 |
| Tamsulosin | 423 | $9,168 | $22 |
| Finasteride | 265 | $5,825 | $22 |
| Tolterodine Tartrate Er | 26 | $3,608 | $139 |
| Dutasteride | 39 | $3,277 | $84 |
| Methenamine Hippurate | 26 | $2,845 | $109 |
| Potassium Citrate Er | 25 | $1,957 | $78 |
| Oxybutynin Chloride Er | 40 | $1,821 | $46 |
| Solifenacin | 21 | $1,781 | $85 |
| Desmopressin Acetate | 15 | $1,303 | $87 |
| Testosterone | 13 | $804 | $62 |
| Alfuzosin Hcl Er | 27 | $574 | $21 |
| Bicalutamide | 11 | $415 | $38 |
| Levofloxacin | 19 | $135 | $7 |
| Hydrochlorothiazide | 28 | $127 | $5 |
| Cephalexin | 13 | $127 | $10 |
| Ciprofloxacin | 21 | $69 | $3 |
2021: 23 drugs
| Myrbetriq | 111 | $70,346 | $634 |
| Finasteride | 242 | $6,160 | $25 |
| Tamsulosin | 330 | $5,761 | $17 |
| Tolterodine Tartrate Er | 44 | $5,159 | $117 |
| Oxybutynin Chloride Er | 47 | $2,919 | $62 |
| Methenamine Hippurate | 17 | $2,321 | $137 |
| Potassium Citrate Er | 13 | $2,028 | $156 |
| Solifenacin | 19 | $1,848 | $97 |
| Dutasteride | 24 | $1,639 | $68 |
| Desmopressin Acetate | 20 | $1,601 | $80 |
| Testosterone | 14 | $1,089 | $78 |
| Alfuzosin Hcl Er | 27 | $567 | $21 |
| Bicalutamide | 16 | $555 | $35 |
| Nitrofurantoin Mono-Macro | 19 | $524 | $28 |
| Oxybutynin Chloride | 15 | $480 | $32 |
| Levofloxacin | 17 | $265 | $16 |
| Amoxicillin-Clavulanate Potass | 26 | $234 | $9 |
| Allopurinol | 11 | $220 | $20 |
| Ciprofloxacin | 39 | $204 | $5 |
| Hydrocodone-Acetaminophen | 25 | $187 | $7 |
| Cephalexin | 28 | $147 | $5 |
| Hydrochlorothiazide | 28 | $124 | $4 |
| Sulfamethoxazole-Trimethoprim | 15 | $48 | $3 |
2020: 17 drugs
| Myrbetriq | 83 | $42,448 | $511 |
| Finasteride | 178 | $3,692 | $21 |
| Tamsulosin | 227 | $3,374 | $15 |
| Testosterone | 14 | $2,921 | $209 |
| Oxybutynin Chloride Er | 47 | $2,531 | $54 |
| Dutasteride | 35 | $2,025 | $58 |
| Tolterodine Tartrate Er | 14 | $1,844 | $132 |
| Nitrofurantoin Mono-Macro | 18 | $668 | $37 |
| Tadalafil | 17 | $636 | $37 |
| Bicalutamide | 16 | $378 | $24 |
| Levofloxacin | 16 | $265 | $17 |
| Alfuzosin Hcl Er | 21 | $257 | $12 |
| Sulfamethoxazole-Trimethoprim | 34 | $248 | $7 |
| Amoxicillin-Clavulanate Potass | 34 | $232 | $7 |
| Hydrocodone-Acetaminophen | 19 | $171 | $9 |
| Ciprofloxacin | 51 | $168 | $3 |
| Cephalexin | 22 | $70 | $3 |
2019: 17 drugs
| Myrbetriq | 99 | $44,073 | $445 |
| Tamsulosin | 182 | $2,893 | $16 |
| Finasteride | 157 | $2,708 | $17 |
| Nitrofurantoin Mono-Macro | 25 | $1,866 | $75 |
| Potassium Citrate Er | 13 | $1,816 | $140 |
| Tolterodine Tartrate Er | 12 | $1,436 | $120 |
| Dutasteride | 23 | $1,218 | $53 |
| Oxybutynin Chloride Er | 13 | $544 | $42 |
| Testosterone Cypionate | 11 | $511 | $46 |
| Alfuzosin Hcl Er | 26 | $424 | $16 |
| Oxycodone-Acetaminophen | 23 | $237 | $10 |
| Levofloxacin | 21 | $224 | $11 |
| Ciprofloxacin | 52 | $204 | $4 |
| Amoxicillin-Clavulanate Potass | 21 | $177 | $8 |
| Sulfamethoxazole-Trimethoprim | 29 | $125 | $4 |
| Hydrocodone-Acetaminophen | 16 | $122 | $8 |
| Cephalexin | 16 | $97 | $6 |
2018: 16 drugs
| Myrbetriq | 71 | $25,962 | $366 |
| Vesicare | 20 | $15,497 | $775 |
| Toviaz | 32 | $15,080 | $471 |
| Rapaflo | 12 | $2,912 | $243 |
| Tamsulosin | 155 | $2,457 | $16 |
| Finasteride | 145 | $2,286 | $16 |
| Nitrofurantoin Mono-Macro | 31 | $1,903 | $61 |
| Tolterodine Tartrate Er | 17 | $1,805 | $106 |
| Potassium Citrate Er | 11 | $1,519 | $138 |
| Dutasteride | 21 | $816 | $39 |
| Alfuzosin Hcl Er | 34 | $517 | $15 |
| Levofloxacin | 15 | $462 | $31 |
| Bicalutamide | 18 | $280 | $16 |
| Oxycodone-Acetaminophen | 18 | $241 | $13 |
| Ciprofloxacin | 55 | $218 | $4 |
| Sulfamethoxazole-Trimethoprim | 20 | $53 | $3 |
2017: 11 drugs
| Vesicare | 44 | $21,075 | $479 |
| Toviaz | 29 | $12,005 | $414 |
| Tolterodine Tartrate Er | 19 | $3,585 | $189 |
| Rapaflo | 12 | $2,736 | $228 |
| Tamsulosin | 81 | $1,428 | $18 |
| Finasteride | 59 | $881 | $15 |
| Bicalutamide | 14 | $283 | $20 |
| Ciprofloxacin | 50 | $190 | $4 |
| Oxycodone-Acetaminophen | 17 | $167 | $10 |
| Hydrocodone-Acetaminophen | 11 | $61 | $6 |
| Sulfamethoxazole-Trimethoprim | 13 | $50 | $4 |
2016: 6 drugs
| Vesicare | 18 | $6,726 | $374 |
| Tamsulosin | 124 | $2,287 | $18 |
| Finasteride | 124 | $1,367 | $11 |
| Bicalutamide | 18 | $290 | $16 |
| Ciprofloxacin | 29 | $144 | $5 |
| Oxycodone-Acetaminophen | 11 | $96 | $9 |
2015: 13 drugs
| Tamsulosin | 296 | $7,344 | $25 |
| Vesicare | 19 | $4,947 | $260 |
| Toviaz | 13 | $4,178 | $321 |
| Finasteride | 281 | $3,026 | $11 |
| Nitrofurantoin Mono-Macro | 60 | $1,386 | $23 |
| Ciprofloxacin | 119 | $904 | $8 |
| Alfuzosin Hcl Er | 27 | $442 | $16 |
| Oxycodone-Acetaminophen | 33 | $407 | $12 |
| Bicalutamide | 23 | $389 | $17 |
| Oxybutynin Chloride | 11 | $209 | $19 |
| Hydrocodone-Acetaminophen | 20 | $103 | $5 |
| Megestrol Acetate | 12 | $55 | $5 |
| Sulfamethoxazole-Trimethoprim | 13 | $53 | $4 |
2014: 18 drugs
| Vesicare | 36 | $10,172 | $283 |
| Toviaz | 30 | $6,610 | $220 |
| Potassium Citrate Er | 25 | $5,539 | $222 |
| Rapaflo | 22 | $4,173 | $190 |
| Tamsulosin | 241 | $4,008 | $17 |
| Finasteride | 211 | $3,515 | $17 |
| Ciprofloxacin | 351 | $1,905 | $5 |
| Nitrofurantoin Mono-Macro | 35 | $1,245 | $36 |
| Bicalutamide | 20 | $1,148 | $57 |
| Bethanechol Chloride | 18 | $1,037 | $58 |
| Oxybutynin Chloride Er | 18 | $851 | $47 |
| Oxybutynin Chloride | 26 | $770 | $30 |
| Oxycodone-Acetaminophen | 86 | $721 | $8 |
| Alfuzosin Hcl Er | 21 | $349 | $17 |
| Hydrocodone-Acetaminophen | 35 | $236 | $7 |
| Hydrochlorothiazide | 18 | $196 | $11 |
| Allopurinol | 16 | $195 | $12 |
| Sulfamethoxazole-Trimethoprim | 17 | $107 | $6 |
2013: 13 drugs
| Vesicare | 32 | $9,163 | $286 |
| Rapaflo | 48 | $7,585 | $158 |
| Toviaz | 30 | $6,522 | $217 |
| Finasteride | 103 | $2,156 | $21 |
| Tamsulosin | 151 | $2,141 | $14 |
| Bethanechol Chloride | 21 | $1,127 | $54 |
| Ciprofloxacin | 167 | $867 | $5 |
| Nitrofurantoin Mono-Macro | 13 | $741 | $57 |
| Oxybutynin Chloride | 21 | $429 | $20 |
| Sulfamethoxazole-Trimethoprim | 47 | $291 | $6 |
| Oxycodone-Acetaminophen | 50 | $248 | $5 |
| Cephalexin | 11 | $100 | $9 |
| Phenazopyridine | 12 | $54 | $4 |
Money from drug and device companies
$162 in 2025
| 2025 | 2 | 4 | None | $162 |
| 2024 | 2 | 2 | None | $192 |
| 2023 | 1 | 3 | None | $251 |
| 2021 | 1 | 1 | None | $92 |
| 2020 | 1 | 2 | None | $381 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Procept Biorobotics | Aquabeam Robotic System | $139 | 3 payments
|
| Coloplast | Supris | $23 | 1 payment
|
See all 4 published payments
| Procept Biorobotics | Meals · 2025-08-14 | Aquabeam Robotic System | $24 |
| Procept Biorobotics | Meals · 2025-08-12 | Aquabeam Robotic System | $4 |
| Procept Biorobotics | Meals · 2025-07-24 | Aquabeam Robotic System | $111 |
| Coloplast | Meals · 2025-03-21 | Supris | $23 |
See earlier years (2024, 2023, 2021, 2020)
2024: $192
| Boston Scientific | Lithovue | $138 | 1 payment
|
| SRS Medical Systems | Ct3000 Pro Base Unit | $54 | 1 payment
|
2023: $251
| Boston Scientific | Lithovue | $251 | 3 payments
|
2021: $92
| Boston Scientific | Lithovue | $92 | 1 payment
|
2020: $381
| Boston Scientific | General - Kidney Stone Disease | $381 | 2 payments
|
Professional record
- NPI
- 1063603108
- Licence
- CA A112593California A112593: Current · expires 2027-11-30
- Trained
- University of Missouri, Columbia School of Medicine, 2004
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- LA 1091430
- Taxonomy
- Urology (208800000X)
- Mailing address
- 2350 W El Camino Real Fl 2, Mountain View, CA, 94040
- NPI first listed
- 2007-08-05
- NPI last updated
- 2018-06-20
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1667 Dominican Way, Santa Cruz, CA, 95065